TuHURA BIOSCIENCES, INC./NV Income Tax Expense
TuHURA BIOSCIENCES, INC./NV (HURA) reported Income Tax Expense of $1.60 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-03-31
- TuHURA BIOSCIENCES, INC./NV income tax expense (benefit) for fiscal 2025 was $1.60K, a 57.54% decline from fiscal 2024.
- TuHURA BIOSCIENCES, INC./NV income tax expense (benefit) for fiscal 2024 was $3.77K.
- TuHURA BIOSCIENCES, INC./NV income tax expense (benefit) for fiscal 2023 was $0.00.
| Period end | Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $1.60K 10-K · filed 2026-03-31 |
| 2024-12-31 | $3.77K 10-K · filed 2026-03-31 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |